Business Wire

ENRY’S-ISLAND

Share
Enry’s Island Secures €20 Million from LDA Capital to Scale the First Accelerator in the Metaverse

Enry’s Island is delighted to announce that they have secured a Euro 20 million capital commitment from LDA Capital , an alternative investment group with expertise in complex, cross-border transactions around the globe, based in Los Angeles, California. Adding to the year’s success, this capital commitment comes just as Enry’s Island prepares to operate on international markets, making them a rising star in the incubation and acceleration world, one of the hottest industries of this current economic environment.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220517005729/en/

“We are excited about our partnership with LDA Capital”, says Luigi Valerio Rinaldi, founder and CEO of Enry’s Island. Over the course of the next few months, the Company will transform into a “S.p.a.” (Italian joint stock company), “allowing the business to scale even faster with LDA’s flexible financing package. We are sure that the relationship with LDA will continue in a mutually gratifying way in the medium and long term horizon, allowing the horses in our stable to become unicorns.”

This new capital commitment of funding will be used to scale Enry’s Island phygital capabilities. Specifically, the areas that the company will focus on are:

  • Expansion in the Metaverse and physical spaces (thanks to Enry’s Island portfolio company Rinascimento 5 )
  • International reach increase, thanks to Enry’s Island Local Companies
  • Add 12x to 36x financial value within 3-5 years
  • Consolidating a worldwide standard protocol for the assessment and evaluation of the startups, based on Enry’s Model intellectual property (IP)

At the forefront of the industry, Enry’s Island is the first Incubation & Acceleration Metaverse (# 1 incubator & accelerator in Italy, & # 6 in Europe according to Crunchbase Q4/2021), with local companies in US, UK, Italy, Spain, Ireland, Africa, a global community of more than 800 stakeholders who include entrepreneurs, investors, and professionals and 30 startups, thoroughly assessed and evaluated based on Enry’s Model, the patented intellectual property the whole organization, processes and tool of Enry’s Island is based on. The Enry’s Model is also part of the “Enry’s Theory ” manual of business management, published by MacGraw-Hill .

About LDA Capital

LDA Capital is a global alternative investment group with expertise in cross border transactions worldwide. Our team has dedicated their careers to international & cross border opportunities having collectively executed over 250 transactions in both the public and private middle markets across 43 countries with aggregate transaction values of over US$11 billion. For more information please visit: www.ldacap.com ; For inquires please email: info@ldacap.com .

About Enry’s Island

  • 15 years of experience in the management of very early stage startups, with a mortality rate of only 10% (against 90% which is the industry average)
  • 12-month incubation and acceleration programs, totally customized to the needs of startups, with investments of € 200k in operational services (not just mentorship)
  • Proprietary patent, Enry's Model , which allows for the evaluation of company performance and value; Enry's Model is also the subject of a McGrawHill manual (which, in view of its success in Europe, has been translated for the US market);
  • Explosive scale up in the last 3 years, going from 8 to 25 companies, from €2M to €40M in portfolio value, from a community of 30 to 800 stakeholders;
  • full remote and totally distributed organization, which has allowed Enry’s Island to grow during the last 2 years of pandemic;
  • A revolutionary corporate architecture, which includes local companies in Ita, US, UK, Africa, Ibiza, Ireland and upcoming openings in the Far East, that do not replicate, but specialize and scale the different EI best practices in the different countries.
  • High information symmetry, given that the whole EI community uses a revolutionary Saas platform (hui.land), which guarantees efficiency and effectiveness in business management and business risk containment; HUI provides KPIs to all internal and external stakeholders, allowing investors to invest directly in target companies through HUI (thanks to crowdfunding campaigns in Europe, US and Canada), directly through HUI;
  • A revolutionary vision and management of space, both physical (having eliminated any physical location, as if it were in a DAO, but using a network of hosts with ideal characteristics for remote working in places with a high quality of life, such as villages, natural areas) and metaverse space (EI has started investing in the metaverse, building its first building in Cryptovoxels and having launched the first investor day entirely in metaverse https://www.cryptovoxels.com/parcels/7328 )

Visit www.enrysisland.com and discover why Enry’s Island has ignited interest from all over the world.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Compass Pathways Announces FDA Acceptance of IND Application for PTSD and Hosts Webinar on PTSD and TRD7.1.2026 12:30:00 CET | Press release

FDA Accepts Investigational New Drug (IND) Application for COMP360 for the treatment of post-traumatic stress disorder (PTSD), enabling initiation of late-stage trialCompass continues to advance commercial preparations to be launch-ready by the end of the year for COMP360 for treatment-resistant depression (TRD)Management will host webinar with KOL and industry leaders to discuss PTSD clinical trial and commercial preparations for TRD from 10:00-11:30 am ET on January 7th Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, today announced that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application for COMP360, enabling the initiation of a late-stage clinical trial in patients with PTSD. Compass management, along with KOL and industry leaders, will host a webinar today to discuss the company’s clinical trial plans for PTSD, as well as commercial preparations f

Stallergenes Greer Expands Venom Immunotherapy Production Capacity With Acquisition of Entomon s.r.l.7.1.2026 11:07:00 CET | Press release

Stallergenes Greer, a global leader in allergy therapeutics, today announced that it has entered into an agreement to acquire Entomon s.r.l., an Italian company specialising in the production of certified stinging-insect venom extracts, notably of the Hymenoptera order, used for the manufacture of diagnostic preparations and Venom Immunotherapy (VIT). The transaction is expected to close by the end of January. Entomon, currently recognised as the only company in Europe capable of extracting pure venom from Hymenoptera insects, produces pharmaceutical-grade insect venom using proprietary techniques (Entomon Capillary Extracted Venom®) for medical use. Through this acquisition, Stallergenes Greer bolsters its venom manufacturing capabilities and supply of raw materials for life-saving VIT treatments, whilst safeguarding patient care continuity. Hymenoptera venom allergy is the most common trigger of severe anaphylaxis in adults1. According to the EAACI guidelines on venom immunotherapy,

ARIS Announces New CEO to Lead Agentic AI-led Strategy7.1.2026 10:00:00 CET | Press release

CEO Appointment ARIS, a global leader in process intelligence and transformation software, today announced the appointment of Guillaume Bacuvier as Chief Executive Officer. Guillaume will lead ARIS through its next phase of growth as a fully standalone company, accelerating its evolution from a market leader in Process Intelligence into a foundational platform for enterprises deploying and governing Agentic AI. Guillaume brings deep international leadership experience across technology, data, and software-enabled businesses, with a proven track record of scaling global platforms and leading complex organisations. After starting as a strategic consultant at Booz Allen Hamilton, Guillaume spent over a decade at Google, rising to Vice President in EMEA where he built and scaled some of Google’s largest data-driven businesses in Europe and held P&L responsibility across multiple countries. In the last decade, Guillaume has served as CEO of multi-continent, data-centric companies including

I Squared Capital Acquires Ramudden Global, a Leader in Traffic Management and Infrastructure Safety7.1.2026 09:00:00 CET | Press release

Acquisition will accelerate Ramudden’s ambitious growth plan across North America and Europe supported by strong infrastructure spending tailwinds I Squared Capital, a leading global infrastructure investment manager, today announced that, through its flagship fund, it has agreed to acquire Ramudden Global, from funds advised by Triton Partners (“Triton”), a leading European mid-market sector-specialist investor. Ramudden Global is a leading international provider of traffic management and infrastructure safety services supporting the maintenance and upgrade of essential transport and utility networks. The company operates more than 190 depots across 13 countries in Europe and North America delivering mission-critical services that help to ensure safety, regulatory compliance and continuity of service across road, utility and broader infrastructure works. This investment underscores I Squared Capital’s commitment to investing in essential, regulated, infrastructure businesses that unde

RoslinCT and BOOST Pharma Announce Strategic Manufacturing Agreement to Advance Cell Therapy for Infants with Osteogenesis Imperfecta7.1.2026 09:00:00 CET | Press release

RoslinCT, a global contract development and manufacturing organization (CDMO) specializing in advanced cell therapies, and BOOST Pharma, a clinical-stage biotechnology company developing first-in-class cell therapies for rare paediatric skeletal diseases, today announced a strategic manufacturing partnership to support the development of BOOST Pharma’s cell therapy, BT-101, for the treatment of infants with Osteogenesis Imperfecta (OI), also known as brittle bone disease. Under the service agreement, BOOST Pharma has transferred its manufacturing process to RoslinCT’s state-of-the-art facilities in Edinburgh, Scotland. The partnership will progress toward GMP manufacturing of starting materials and clinical drug product, supporting Phase III clinical development of BT-101. The therapy is an allogeneic mesenchymal stem cell (MSC) product designed to address the underlying cause of OI at the earliest stages of life. BOOST Pharma was founded on pioneering science originating from Karolins

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye